maintaining our $365 fair value estimate for Regeneron after third-quarter results that were below expectations, with U.S. Eylea sales growing less than expected and ..... diabetic macular edema (DME) would allow Eylea sales to accelerate more rapidly into ..... recent superior top-line results of Eylea versus Lucentis and Avastin in a National
Nov 4 (Reuters) - Regeneron Pharmaceuticals Inc reported a higher quarterly revenue on increased sales of its eye injection Eylea .
We are slightly raising Regeneron 's FVE to $365 per share (from ..... macular edema, which showed that Eylea demonstrated better efficacy and safety ..... patent infringement lawsuit against Regeneron /Sanofi’s PCSK9 drug, Alirocumab
Regeneron reported second-quarter results that ..... better than anticipated, with U.S. Eylea sales rebounding strongly after a sluggish ..... first-quarter results. Rest of world Eylea sales, as reported by partner Bayer ..... Despite higher SG&A costs related to Eylea 's commercialization and increased ..... hypercholesterolemia patients. Importantly, Regeneron also disclosed that in a prespecified
Regeneron has reported two meaningful pipeline ..... Food and Drug Administration approved Eylea on July 29 in diabetic macular edema ..... treating high cholesterol. While the Eylea news was expected, the positive alirocumab ..... narrow moat, positive trend rating for Regeneron . While the DME approval was expected ..... estimates, the new indication should allow Eylea sales to re-accelerate in the second
Regeneron reported first-quarter results that ..... disappointing due to sluggish sales of Eylea in the U.S. However, the company ..... first quarter of 2013. Revenue included Eylea U.S. net product sales of $359 million ..... market share trends. Rest-of-world Eylea sales, as reported by partner Bayer
(Reuters) - The Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said...
expected tax rate starting in 2017. Regeneron continues to make progress in expanding Eylea ’s label into additional indications ..... and increased R&D spending tied to Regeneron 's expansive clinical and research program, strong Eylea growth helped the firm increase its profit. Regeneron reported adjusted earnings per share
(Reuters) - Regeneron Pharmaceuticals Inc forecast U.S. sales of eye drug Eylea to reach $1.7-$1.8 billion in 2014 as it expects the drug to win approval for newer uses, sending its shares up 3...
Sciences and others across the complex, often with successful results. In fact, health-care picks such as Regeneron Pharmaceuticals REGN have been big contributors to many diversified funds in recent years, meaning the departures were felt well